

FOR IMMEDIATE RELEASE



June 24, 2013

AnGes MG, Inc.

### **Phase I Study Starts for NF- $\kappa$ B Decoy Oligo Atopic Dermatitis Treatment Drug**

AnGes MG, Inc. ("AnGes") today announced the initiation of a Phase I clinical study of topical NF- $\kappa$ B decoy oligo formulation for atopic dermatitis treatment, a co-development project with Shionogi & Co., Ltd. (Head Office: Osaka, President and Representative Director, Isao Teshirogi, "Shionogi").

AnGes and Shionogi reached an agreement concerning the initiation of the Phase I study as announced by AnGes on April 17, 2013. AnGes is pleased to announce that the administration of the drug in subjects has begun.

Efficacy of NF- $\kappa$ B decoy oligo has already been confirmed in clinical trials of the previously developed NF- $\kappa$ B decoy oligo ointment drug, conducted in patients with moderate and severe atopic dermatitis. A topical NF- $\kappa$ B decoy oligo drug is expected to become an external preparation for skin, with a new function that is less irritating to the skin. This Phase I study examines the safety of the NF- $\kappa$ B decoy oligo, which uses a new formulation with improved skin penetration.

AnGes is to receive milestone payments from Shionogi upon the start of the Phase I study. The effect on business performance for the fiscal year 2013 is already included in the forecast announced on February 7, 2013. The forecast may be revised with a number of other factors, and AnGes intends to review its forecast and announce a revision when necessary.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
---